The European Medicines Agency (EMA) is drafting an outline that will clarify what products can be produced in multi-product facilities without contamination.  The assessment is focusing on toxicological data that is, at times, overlooked when determining limits of cross contamination.  The final guidance will be issued in early 2013 after a three month trial in June 2012, after which, input will be taken to finalize the text.

To read the full article from in-Pharma, go here.